Skip to main
REPL

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group Inc. has increased the probability of approval for its RP1 + Opdivo combination therapy in anti-PD1 failed melanoma patients to 85%, reflecting strong confidence in the clinical efficacy of its product pipeline. The company reported a favorable safety profile for RP1 + Opdivo, with only 12.8% of patients experiencing grade 3 or higher treatment-related adverse events, which may further support regulatory approval. These positive developments, alongside promising trial results, enhance the company's outlook as it continues to focus on innovative oncolytic immunotherapies for cancer treatment.

Bears say

Replimune Group faces significant risks that jeopardize its future prospects, primarily stemming from its inability to generate compelling efficacy and safety data for its lead product, RP1, in upcoming clinical trials. Concerns raised by the FDA regarding the adequacy of the IGNYTE trial and the heterogeneity of the patient population hinder the credibility of the clinical evidence supporting RP1, further complicating potential regulatory approvals. Additionally, the company may encounter medium- to long-term dilution risk, which could negatively impact shareholder value as it strives to deliver on its early-stage pipeline of oncolytic virus candidates.

REPL has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 8 analysts, REPL has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.